Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2025 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice ConferenceDosing of first patient in THRIVE-3...
March 05, 2025 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025Dosing of first patient in...
February 26, 2025 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
February 05, 2025 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
January 13, 2025 08:00 ET | Source: Protara Therapeutics

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month...
January 08, 2025 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
December 11, 2024 16:05 ET | Source: Protara Therapeutics

Protara Announces Closing of $100 Million Public Offering

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
December 09, 2024 23:35 ET | Source: Protara Therapeutics

Protara Announces Pricing of $100 Million Public Offering

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
December 09, 2024 16:01 ET | Source: Protara Therapeutics

Protara Announces Proposed Public Offering

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
December 05, 2024 07:00 ET | Source: Protara Therapeutics

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete...